Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma
Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Activating mutations in the driver oncogene KRAS occur in 32% of lung adenocarcinomas, leading to more aggressive disease and resistance to therapy in preclinical studies. However, the association between KRAS mutational status and patient outcome or response to treatment remains unclear, likely due to additional events modulating RAS pathways. To...
Alternative Titles
Full title
Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2508569122
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2508569122
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/2021.04.02.437896
How to access this item
https://www.proquest.com/docview/2508569122?pq-origsite=primo&accountid=13902
